Brazil's health regulatory agency, Anvisa, has reportedly approved Ozivy, the first domestic synthetic semaglutide weight-loss pen [1].
This development follows the expiration of the patent for Ozempic on March 20, 2024 [1]. The end of this legal protection allows Brazilian pharmaceutical companies to produce generic versions of the drug, potentially lowering costs for patients seeking weight-loss and diabetes treatments.
However, conflicting reports exist regarding the current status of these approvals. While CNN Brasil said Ozivy was approved Tuesday [1], other reports indicate that Anvisa is still in the process of examining eight new semaglutide-based medicines [2]. These sources said that no formal approval for a specific domestic equivalent has been finalized yet [2].
Semaglutide is the active ingredient in Ozempic, a medication originally designed for type 2 diabetes that gained global popularity for weight management. The introduction of synthetic, locally produced versions in Brazil represents a shift toward domestic drug manufacturing for high-demand metabolic treatments.
Anvisa is tasked with ensuring that any synthetic equivalent meets the same safety and efficacy standards as the original patented drug. The agency continues to evaluate the applications to determine which products can enter the Brazilian market [2].
Because the patent expired in March 2024 [1], the market has seen a surge in applications from domestic firms. The agency is currently reviewing the technical data for the eight pending medications to verify their chemical composition, and delivery mechanisms [2].
“Anvisa reportedly approved Ozivy, the first domestic synthetic semaglutide weight-loss pen.”
The potential arrival of domestic semaglutide pens in Brazil could significantly disrupt the market for expensive weight-loss medications. By shifting from a single-patent holder to a competitive environment with multiple generic options, the cost of treatment may decrease, increasing accessibility for the general population while challenging the market dominance of international pharmaceutical firms.
